HONG KONG SAR - Media OutReach Newswire - 26 January 2026 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today the initiation of a Phase I clinical study ...
Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means that people living with HIV need to take lifelong antiretroviral treatment. But ...
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...
Using participant skin cells reprogrammed into neurons, Weill Cornell Medicine researchers have identified genetic signatures ...
Benjamin K. Chen, MD, PhD, discussed the next steps after the results of his study in genetic tagging showed promise in targeting HIV cells. How do you envision gene therapy working with other forms ...
A therapy originally developed for HIV now provides new options for patients with rare genetic disorders. It’s now possible to use these drugs to address DNA defects and enhance muscle function. This ...
CHICAGO--(BUSINESS WIRE)--Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to ...
Investigators from Whitehead Institute, the Ragon Institute of MGH, MIT and Harvard and the Broad Institute of MIT and Harvard have used CRISPR-Cas9 gene-editing technology to identify three promising ...
Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results